Depatuxizumab mafodotin

DRUG3 trials

Conditions

GlioblastomaGlioblastoma MultiformeGliosarcoma

Phase 2

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

CompletedNCT02343406

AbbVieGlioblastoma

Start: 2015-02-17End: 2019-06-24Updated: 2020-05-22

Phase 3

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

CompletedNCT02573324

AbbVieGlioblastoma, Gliosarcoma

Start: 2015-01-04End: 2022-04-04Updated: 2023-05-11

UNITE Study: Understanding New Interventions With GBM ThErapy

TerminatedNCT03419403

AbbVieGlioblastoma Multiforme

Start: 2018-07-30End: 2020-03-03Updated: 2021-04-14

2026-01-09

A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin

Ophthalmic Research2023-01-014 citations

Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial

Cancer Science2021-10-0722 citations

Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.

2021-02-1517 citations

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Neuro-Oncology2019-11-19180 citations

ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)

Neuro-Oncology2019-11-0125 citations

ACTR-21. MANAGEMENT OF OCULAR SIDE EFFECTS IN PATIENTS WITH EGFR-AMPLIFIED GLIOBLASTOMA RECEIVING DEPATUXIZUMAB MAFODOTIN

Neuro-Oncology2018-11-01

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with<i>EGFR</i>-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Neuro-Oncology2018-06-1194 citations

HGG-15. PHASE 2 NESTED COHORT STUDY OF DEPATUXIZUMAB MAFODOTIN IN CHILDREN WITH HIGH GRADE GLIOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA WITH EGFR AMPLIFICATION

Neuro-Oncology2018-06-01

Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).

Journal of Clinical Oncology2018-05-2013 citations

LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410

Neuro-Oncology2017-11-0113 citations

ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)

Neuro-Oncology2017-11-018 citations

PDCT-02. EVALUATION OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN CHILDREN WITH HIGH GRADE GLIOMA (HGG) AND DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Neuro-Oncology2017-11-011 citations

ACTR-13. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA

Neuro-Oncology2017-11-011 citations

QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA

Neuro-Oncology2017-11-011 citations

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

2017-10-2699 citations

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

Neuro-Oncology2017-10-2176 citations

Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.

Journal of Clinical Oncology2017-05-209 citations

OS07.4 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM)

Neuro-Oncology2017-04-015 citations

ACTR-07. EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM)

Neuro-Oncology2016-11-012 citations

2 more papers not shown

Depatuxizumab mafodotin

Sponsors

Conditions

Phase 2

Phase 3

Related Papers